Source-grounded facts extracted from PURE BIOSCIENCE, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PURE BIOSCIENCE, INC. entered into Securities Purchase Agreement with certain accredited investors valued at $1.0 million (effective 2026-04-30).
“ssued in the Private Placement Financing were issued pursuant to a Securities Purchase Agreement (the “Securities Purchase Agreement”) entered into with the Investors.”
Darin Zehr was appointed as Director at PURE BIOSCIENCE, INC..
“On May 1, 2024, the Board of Directors (the “Board”) of Pure Bioscience, Inc. (the “Company”) authorized and appointed Darin Zehr, as a member of the Board.”
PURE BIOSCIENCE, INC. incurred convertible notes of $500,000 with certain accredited investors at 7.81%, compounded annually maturing the third-year anniversary of the date of issuance.
“On March 22, 2024, Pure Bioscience, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (“Lenders”) pursuant to which the Company issued the Lenders convertible promissory notes (the “Notes”, collectively with the Note Purchase Agreement, the “Notes Documents”) with an aggregate principal balance of $500,000 (the “Private Placement”).”
PURE BIOSCIENCE, INC. entered into Note Purchase Agreement with certain accredited investors valued at $500,000 (effective 2024-03-22).
“On March 22, 2024, Pure Bioscience, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (“Lenders”) pursuant to which the Company issued the Lenders convertible promissory notes (the “Notes”, collectively with the Note Purchase Agreement, the “Notes Documents”) with an aggregate principal balance of $500,000 (the “Private Placement”).”
PURE BIOSCIENCE, INC. reported the six months ended January 31, 2024 results: revenue $1,043,000, net income $1,737,000, EPS ($0.02) per share.
“Net product sales were $1,043,000 and $863,000 for the six months ended January 31, 2024 and 2023, respectively. The increase of $180,000 was attributable to increased sales across our end user and distribution network. ● Net loss for the six months ended January 31, 2024 was $1,737,000, compared to $2,053,000 for the six months ended January 31, 2023. ● Net loss, excluding share-based compensation, for the six months ended January 31, 2024 was $1,593,000, compared to $1,842,000 for the six months ended January 31, 2023. ● Net loss per share was ($0.02) for the six months ended January 31, 2024 and 2023, respectively.”
PURE BIOSCIENCE, INC. reported the fiscal second quarter ended January 31, 2024 results: revenue $325,000, net income $1,002,000, EPS ($0.01) per share.
“Net product sales were $325,000 and $396,000 for the fiscal second quarter ended January 31, 2024 and 2023, respectively. The decrease of $71,000 was attributable to decreased sales across our end user network. ● Net loss for the fiscal second quarter ended January 31, 2024 was $1,002,000, compared to $1,060,000 for the fiscal second quarter ended January 31, 2023. ● Net loss, excluding share-based compensation, for the fiscal second quarter ended January 31, 2024 was $938,000, compared to $993,000 for the fiscal second quarter ended January 31, 2023. ● Net loss per share was ($0.01) for the fiscal second quarters ended January 31, 2024 and 2023, respectively.”
PURE BIOSCIENCE, INC. shareholders approved Amendment to Certificate of Incorporation to increase authorized shares from 150,000,000 to 200,000,000 at the 2024-02-21 meeting.
“For Against Abstentions 61,666,543 2,226,172 314,817”
PURE BIOSCIENCE, INC. shareholders approved Adoption of the 2024 Equity Incentive Plan at the 2024-02-21 meeting.
“For Against Abstentions Broker Non-Votes 48,041,487 401,589 3,566,917 12,237,539”
PURE BIOSCIENCE, INC. shareholders approved Executive Compensation (non-binding advisory vote) at the 2024-02-21 meeting.
“For Against Abstentions Broker Non-Votes 48,049,734 412,190 3,548,069 12,237,539”
PURE BIOSCIENCE, INC. shareholders approved Ratification of Auditors at the 2024-02-21 meeting.
“For Against Abstentions 63,801,664 268,958 176,910”
PURE BIOSCIENCE, INC. shareholders approved Election of Directors at the 2024-02-21 meeting.
“Director For Withheld Broker Non-Votes Tom Y. Lee, CPA 51,623,453 386,540 12,237,539 Ivan Chen 51,598,411 411,582 12,237,539 Tom Myers 51,643,956 366,037 12,237,539 David M. Rendall 51,637,237 372,756 12,237,539 Robert Bartlett 51,667,737 342,256 12,237,539 Bernard Blotner 50,457,923 1,552,070 12,237,539”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.